BIFRF (Biofrontera AG) GF Score: 58/100 (As of Jul. 04, 2026) — 14% Above Median


BIFRF Biofrontera AG BIFRF
58 GF Score
Price $22.68
GF Value $31.34
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG GF Score?

Biofrontera AG BIFRF 58 GF Score is 58 as of Jul. 04, 2026, which is 14% above its 10-year median of 51.00. GuruFocus rates BIFRF with a GF Score™ of 58/100 and a GF Value™ of $31.34. The stock has 4 warning signs investors should review.

Biofrontera AG has the GF Score of 58, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 2/10
3. Growth Rank : 1/10
4. GF Value Rank : 9/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Biofrontera AG might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Biofrontera AG  (OTCPK:BIFRF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Biofrontera AG GF Score Related Terms

BIFRF vs ZTS, UTHR, VTRS: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofrontera AG GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's GF Score distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's GF Score falls into.


BIFRF
58GF Score
Biofrontera AG BIFRF
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 58 mean?
Biofrontera AG (BIFRF) has a GF Score of 58 as of Jul. 04, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Biofrontera AG and its competitors. This is 14% above median its historical median of 51.00. Over the past decade, Biofrontera AG's GF Score has ranged from 19.00 to 71.00.
Is Biofrontera AG's GF Score too high?
Biofrontera AG's current GF Score of 58 is 14% above median its 10-year median of 51.00. Over the past 10 years, this metric has ranged from a low of 19.00 to a high of 71.00. Overall, Biofrontera AG has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's GF Score compare to ZTS and UTHR?
Biofrontera AG's GF Score of 58 can be compared against companies in the Drug Manufacturers industry. Historically, Biofrontera AG's own GF Score has ranged from 19.00 to 71.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current GF Score is 58, which is 14% above median its own 10-year median of 51.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (BIFRF) has a current GF Score of 58. The stock's GF Value™ is $31.34, compared to a current price of $22.68 — trading 27.6% below its estimated fair value. The current GF Score is 58, which is 14% above median its 10-year median of 51.00. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Biofrontera AG (BIFRF), the current GF Score is 58 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera AG (BIFRF) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of $22.68 is trading 27.6% below its estimated GF Value™ of $31.34.

Key valuation signals for BIFRF:

  • GF Score: 58 (14% above median its 10-year median of 51.00)
  • GF Value™: $31.34 vs. price of $22.68 (27.6% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the BIFRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score

Get the complete analysis for BIFRF

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.68
Price
$31.34
GF Value